Aprea reports Q2 2026 results, faster enrollment in APR-1051 trial
Aprea Therapeutics said patient enrollment in its Phase 1 WEE1 inhibitor study is picking up as it ended the quarter with $41.2 million in cash.
SEC filing
Latest
2 stories
Wednesday, August 12
Monday, August 3
Lipocine appoints Michael Grissinger to board of directors
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
SEC filing